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Abstract
Aims TIMI risk score and GRACE risk model are widely
available and accepted scores for risk assessment in
STEMI patients and include predictors of poor outcomes.
CHA2DS2-VASc is a validated score for predicting
embolic/stroke risk in patients with non-valvular atrial
fibrillation. Its components contribute to the worse prog-
nosis following myocardial infarction. The advantage of
the CHA2DS2-VASc score in comparison with other risk
scores is that it provides a comprehensive, fast, and simple
method for physicians in risk evaluation that requires no
calculators or computers. Therefore, we have set out to
examine the prognostic significance of CHA2DS2-VASc
score following STEMI in diabetic patients without AF.
Methods A total of 472 patients with diabetes mellitus and
STEMI undergoing primary PCI were enrolled. Based on
the estimated CHA2DS2-VASc score, the study population
was divided into three groups: group 1 (N = 111) with a
moderate CHA2DS2-VASc score of 2 or 3; group 2
(N = 257) with a high CHA2DS2-VASc score of 4 or 5;
and group 3 (N = 104) with a very high CHA2DS2-VASc
score of 6 or higher.
Results In diabetic patients with STEMI, the median of
CHA2DS2-VASc score was 4 (interquartile range 3–5). In-
hospital mortality rate was similar across three groups.
CHA2DS2-VASc score was not a risk factor of in-hospital
mortality. ROC analysis revealed good diagnostic value of
CHA2DS2-VASc score in predicting long-term mortality
(AUC 0.62 95 % CI 0.57–0.66 P = 0.0003) and stroke
(AUC 0.75 95 % CI 0.71–0.79 P = 0.0003), but no value
in predicting long-term myocardial infarction. CHA2DS2-
VASc score was an independent predictor of 12-month
mortality and stroke. One-point increment in CHA2DS2-
VASc score was associated with an increase in the risk of
12-month death by 24 % and for 12-month stroke by
101 %.
Conclusions In diabetic patients with STEMI and no pre-
viousAF,medianCHA2DS2-VASc scorewas high (4 points)
and predicted 12-month death and stroke. However, it failed
to predict in-hospital death and 12-month MI. CHA2DS2-
VASc score had a similar discrimination performance in
predicting 12-monthmortality as TIMI risk score and a better
discrimination performance in predicting 12-month stroke
than TIMI risk score. Thus, it can serve as an additive tool in
identifying high-risk patients that require aggressive
management.
Keywords STEMI  Diabetes mellitus  Risk score 
CHA2DS2-VASc  Prognosis
Introduction
Outcomes following ST-segment elevation myocardial
infarction (STEMI) have improved over the past two dec-
ades. Nevertheless, survivors of STEMI have an elevated
risk of subsequent vascular events, including stroke and
12-month mortality approaches 10 % [1]. Risk stratifica-
tion following STEMI plays an essential role in managing
patients and is recommended prior to discharge by the
current guidelines. TIMI risk score and GRACE risk model
are widely available and accepted scores for risk
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assessment and include predictors of poor outcomes which
were established in large databases of MI patients [2–4].
The algorithms aid clinicians in assessing prognosis and
may therefore be useful in guiding management. These two
models are both fitted for predicting short- and long-term
prognosis and assess the risk in a two-step process which
includes: (1) stratifying patients at admission based on
demographics, physical examination, presenting signs, and
initial laboratory and angiographic data, and (2) identifying
long-term risk based on the development of post-event
complications. These scores were designed to be simple
and practical, although they comprise numerous variables.
Evidence suggests that diabetes mellitus (DM) is among
the most important risk factors of poor outcome following
STEMI. DM is one of the components of the CHA2DS2-
VASc score. Such a high incidence of thromboembolic
events observed in these clinical subsets may be
attributable to the DM-related prothrombotic state [5].
Generally, the diagnosis of DM is pivotal to assess car-
diovascular risk and to guide therapy and lifestyle modi-
fication. Particularly, this topic is especially relevant for
those patients who have already experienced a major car-
diovascular event [6]. In addition, the presence of coronary
artery disease is a prognostic factor in DM complications
[7, 8]. Accurate risk assessment together with regular fol-
low-up may result in a lower glycemic burden and a lower
rate of vascular complications [9].
CHADS2 and the more recent CHA2DS2-VASc are two
validated scores for predicting embolic/stroke risk in
patients with non-valvular atrial fibrillation (AF) [10, 11].
They aid us in guiding antithrombotic therapy in AF
patients. The individual score components not only predict
AF-associated stroke risk but also are linked to the devel-
opment of AF [12–14]. The CHADS2 and CHA2DS2-VASc
scores have been reported to identify post-STEMI patients
at high risk of AF and ischemic stroke [14].
In addition to predicting the risk of stroke/embolic
events in AF patients, CHA2DS2-VASc score components
(i.e., increasing age, hypertension, diabetes mellitus, prior
cardiovascular events) are traditional risk factors that are
associated with atherosclerosis, coronary artery disease,
and contribute to the worse prognosis following myocardial
infarction (MI). However, only a few studies have exam-
ined the prognostic value of CHA2DS2-VASc following MI
[15, 16], and no studies have been found to evaluate
CHA2DS2-VASc among STEMI or diabetic populations
exclusively.
The advantage of the CHA2DS2-VASc score in com-
parison with other risk scores is that it provides a com-
prehensive, fast, and simple method for physicians in risk
evaluation that requires no calculators or computers.
Therefore, we have set out to examine the prognostic sig-
nificance of CHA2DS2-VASc score following STEMI in
diabetic patients. In the interest of averting a possible effect
of AF on the outcomes, we have performed the analysis in
a population of patients without AF.
Materials and methods
The study conforms to the Declaration of Helsinki.
Informed consent for data analysis was obtained from the
patients according to the Polish law on patients’ rights
regarding data registration. Approval for analyzing recor-
ded data was waived by the local bioethics committee on
human research given the retrospective nature of the study.
Patients admitted with diagnosis of STEMI, within 12 h
from symptom onset were enrolled in the study. Patients
with a history of or newly diagnosed AF were excluded.
This is a single-center, cross-sectional, retrospective study.
A total of 472 patients with diabetes mellitus and
STEMI undergoing primary PCI were enrolled. Based on
the estimated CHA2DS2-VASc score, the study population
was divided into three groups: group 1 (N = 111) with a
moderate CHA2DS2-VASc score of 2 or 3; group 2
(N = 257) with a high CHA2DS2-VASc score of 4 or 5;
and group 3 (N = 104) with a very high CHA2DS2-VASc
score of 6 or higher.
The components of CHA2DS2-VASc score include:
congestive heart failure (1 point), hypertension (1 point),
age[75 years (2 points), diabetes mellitus (1 point), his-
tory of stroke (2 points), history of vascular disease (1
point), age[65 years (1 point), and female sex (1 point)
[11]. The history of myocardial infarction was regarded as
‘vascular disease’, and the current STEMI was counted as 1
point. As the study investigated only diabetic patients, all
patients have received a minimum score of 2 points.
All patients received loading doses of antiplatelet
medications (aspirin, clopidogrel) before admission to our
hospital (either in the referring hospital or ambulance)
according to the guidelines. Diabetes mellitus was defined
as: (a) preexisting condition diagnosed before STEMI
(patients on insulin, oral glucose-lowering drugs, or on a
diet) and (b) newly diagnosed diabetes mellitus based on
fasting plasma glucose (FPG) C7.0 mmol/L or 2-h plasma
glucose C11.1 mmol/L during an oral glucose tolerance
test (OGTT) [17]. To avoid acute hyperglycemia, FPG was
taken into consideration after the third day of hospital stay.
For that reason, OGTT was performed on day four of
hospital stay or later. STEMI was defined as: (1) ST-seg-
ment elevation consistent with MI of at least 2 mm in
contiguous precordial leads and/or ST-segment elevation
of at least 1 mm in two or more limb leads or new left
bundle branch block, and (2) positive cardiac necrosis
markers: CK-MB mass (upper limit of normal: 4.9 mg/mL)
and/or troponin T (upper limit of normal: 0.014 ng/mL).
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Patients received 300 mg of acetylsalicylic acid (ASA)
loading dose and 600 mg of clopidogrel loading dose,
followed by 75 mg of ASA maintenance dose and 75 mg
of clopidogrel maintenance dose [18]. Coronary angiog-
raphy and percutaneous coronary interventions were per-
formed using standard protocols and guidelines. A culprit
lesion was described in the presence of an acute occlusion,
intraluminal filling defects (or thrombus), ulcerated pla-
ques, dissection, or intraluminal flaps. Successful PCI was
defined as a post-procedural residual-diameter stenosis
\30 %, with TIMI 3 flow in the infarct-related artery and
no procedural complications.
All patients were scheduled for an elective 12-month
clinical follow-up. We clinically monitored the patients for
cardiovascular events. The major adverse cardiac and
cerebrovascular events (MACCEs) included death, rehos-
pitalization for myocardial infarction, and stroke.
Statistical analysis
Quantitative data are presented as means ± standard
deviations (SDs) or medians with interquartile ranges
(lower and upper quartiles). Qualitative data are presented
as frequencies. The Shapiro–Wilk test was used to deter-
mine whether random samples came from a normal dis-
tribution. The Chi-square test with Yates’ correction was
used to compare categorical variables. One-way analysis of
variance (ANOVA) and Kruskal–Wallis ANOVA tests
were used to compare continuous variables between groups
for variables normally and not normally distributed,
respectively. In-hospital and one-year survival was esti-
mated with the Kaplan–Meier method and compared with
the log-rank test. The relationship between CHA2DS2-
VASc score and clinical variables was evaluated by
Spearman’s rank correlation coefficient. Receiver-operat-
ing characteristic (ROC) curves were estimated for
CHA2DS2-VASc score. ROC analysis was used to deter-
mine the cutoff values of CHA2DS2-VASc score to predict
in-hospital and 12-month mortality, myocardial infarction,
and stroke. The effects of the clinical and angiographic
variables on the in-hospital and 12-month mortality were
assessed using the multivariate Cox proportional hazard
regression models with the results expressed as hazard
ratios (HRs) and 95 % confidence intervals (CIs). Vari-
ables with a significant influence on mortality in univariate
analysis were entered into the multivariate model. These
included: history of myocardial infarction, left ventricular
ejection fraction (per 1 % increment), success of PCI (final
TIMI 3 flow) in the culprit vessel, cardiogenic shock, and
time form symptom onset (per 1-h increment). Variables
with a significant influence on 12-month stroke in uni-
variate analysis were entered into the multivariate model.
These included: history of myocardial infarction, anterior
myocardial infarction on admission, and left ventricular
ejection fraction (per 1 % increment).
A value of P\ 0.05 was considered significant.
Results
In diabetic patients with STEMI, the median of CHA2DS2-
VASc score was 4 (interquartile range 3–5). The number of
patients falling in each CHA2DS2-VASc score category is
depicted in Fig. 1. Baseline clinical characteristics are
featured in Table 1. Patients with moderate CHA2DS2-
VASc score (group 1) were younger and more frequently
men. Hypertension and a lower ejection fraction were more
prevalent among patients with a high and very high
CHA2DS2-VASc score (groups 2 and 3). Angiographic
data are presented in Table 2. There was a trend toward a
worse initial TIMI flow in group 3. Initial TIMI 3 flow was
the least prevalent in group 3. Notwithstanding, final TIMI
flow was similar in all three groups. ROC analysis
demonstrated no value of CHA2DS2-VASc score in pre-
dicting in-hospital mortality AUC 0,503 (95 % CI
0.463–0.555) P = 0.83. In-hospital mortality rate was
similar across three groups (Fig. 2a). CHA2DS2-VASc
score was not a risk factor of in-hospital mortality
(Table 3). During 12-month follow-up, there were 10
deaths (9.0 %) in group 1, 43 deaths (16.7 %) in group 2,
and 27 deaths (16.2 %) in group 3 (P = 0.003) (Table 3;
Fig. 2b). The rate of non-fatal myocardial infarction was
similar across all groups, and the rate of stroke was higher
in group 3 (Table 4; Fig. 3a, b). ROC analysis revealed
good diagnostic value of CHA2DS2-VASc score in pre-
dicting 12-month mortality and stroke, but no value in
predicting 12-month myocardial infarction (Tables 5, 6;
Fig. 4a, b). CHA2DS2-VASc score was an independent
predictor of 12-month mortality and stroke. One-point
increment in CHA2DS2-VASc score was associated with an
Fig. 1 Number of patients falling in each CHA2DS2-VASc score
category
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increase in the risk of 12-month death by 24 % and for
12-month stroke by 101 %. CHA2DS2-VASc score was
positively correlated with age (Spearman R = 0.67
P\ 0.0001) and TIMI risk score (Spearman R = 0.40
P\ 0.0001), and negatively correlated with ejection frac-
tion (Spearman R = 0.28 P\ 0.0001), time to stroke
during follow-up (Spearman R = -0.13 P = 0.003), and
time to death during follow-up (Spearman R = -0.15
P = 0.001).
Discussion
In the current study, we have set out to investigate the
utility of CHA2DS2-VASc score in predicting poor out-
comes in patients with diabetes mellitus and STEMI. In
particular, we have sought to determine whether CHA2-
DS2-VASc score commonly used for prediction of throm-
boembolic events in AF patients can be used as a risk
assessment tool in STEMI patients without AF.








Age, years (mean ± SD) 57 ± 8 64 ± 8 73 ± 6 0.0001
Sex, men, N (%) 106 (95.5 %) 150 (58.4 %) 15 (14.4 %) 0.0001
Systemic hypertension, N (%) 41 (36.9 %) 198 (77.0 %) 100 (96.1 %) 0.0001
Anterior myocardial infarction, N (%) 34 (30.6 %) 89 (34.6 %) 36 (34.6 %) 0.7
Prior myocardial infarction, N (%) 34 (30.6 %) 78 (30.5 %) 32 (30.8 %) 0.9
Time from symptom onset, hours [median (interquartile range)] 5.0 (3.0–7.0) 4.5 (3.0–7.0) 4.5 (3.0–7.5) 0.3
Cardiogenic shock, N (%) 15 (13.5 %) 33 (12.8 %) 16 (15.4 %) 0.8
LVEF, (%) [median (interquartile range)] 50 (41–55)* 40 (35–46)* 40 (35–45)* 0.0001
Hospital stay, days [median (interquartile range)] 8 (6–11) 9 (6–12) 8 (6–12) 0.09
TIMI risk score 3 (2–4)§ 3 (2–5)§ 4 (3–6)§ \0.0001
HbA1c (%) [median (interquartile range)] 7.6 (7.0–8.0) 7.6 (6.9–8.0) 7.5 (6.9–8.2) 0.9
Admission glycemia (mmol/l) [median (interquartile range)] 8.1 (7.0–11.4) 7.8 (6.8–10.2) 8.0 (6.2–10.3) 0.2
Fasting plasma glucose (mmol/L) [median (interquartile range)] 6.7 (5.3–7.8) 6.8 (5.8–7.9) 6.6 (5.2–8.3) 0.6
In-hospital death, N (%) 17 (15.3 %) 30 (11.7 %) 17 (16.3 %) 0.4
SD standard deviation, LVEF left ventricular ejection fraction
* Group 1 versus group 2 P\ 0.001, group 1 versus group 3 P\ 0.001, and group 2 versus group 3 P = 0.7
 Group 1 versus group 2 P\ 0.0001, group 1 versus group 3 P\ 0.0001, and group 2 versus group 3 P\ 0.0001
§ Group 1 versus group 2 P = 0.01, group 1 versus group 3 P\ 0.0001, and group 2 versus group 3 P\ 0.0001
Table 2 Angiographic findings
Group 1 N = 111 Group 2 N = 257 Group 3 N = 104 P
Multivessel CAD, N (%) 49 (44.1 %) 117 (45.5 %) 47 (45.2 %) 0.6
Initial TIMI flow, N (%)
0 63 (56.8 %) 150 (58.6 %) 56 (53.8 %) 0.08
1 18 (16.2 %) 46 (17.9 %) 18 (17.3 %)
2 14 (12.6 %) 35 (13.7 %) 25 (24.0 %)
3 16 (14.4 %) 26 (10.1 %) 5 (4.8 %)
Initial TIMI 3 flow, N (%) 16 (14.4 %) 26 (10.1 %) 5 (4.8 %) 0.05
Final TIMI flow, N (%)
0 5 (4.5 %) 17 (6.6 %) 8 (7.1 %) 0.8
1 1 (0.9 %) 3 (1.2 %) 2 (1.9 %)
2 11 (10.0 %) 19 (7.4 %) 9 (8.7 %)
3 94 (84.6 %) 218 (85.1 %) 85 (81.3 %)
Final TIMI 3 flow, N (%) 94 (84.6 %) 218 (85.1 %) 85 (81.3 %) 0.7
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There are several major findings of the study. First and
foremost, CHA2DS2-VASc score was high across the entire
study population with a median of 4 points. Second, it had
no influence on the in-hospital mortality. The third major
finding was that CHA2DS2-VASc score, both unadjusted
and adjusted for potential cofounders, correlated with
12-month stroke and all-cause mortality, but it had no
influence on 12-month myocardial infarction. CHA2DS2-
VASc score showed similar predictive value with respect
to 12-month mortality as TIMI risk score. More impor-
tantly, it demonstrated a better predictive value with
respect to 12-month stroke than TIMI risk score. And
finally, CHA2DS2-VASc score showed a negative correla-
tion with the time to subsequent stroke or death during
follow-up.
CHADS2 score was developed to identify AF patients at
risk for stroke or thromboembolic event and thus to guide
anticoagulation therapy [10]. However, patients with an
intermediate risk (CHADS2 score 1) presented a challenge
in everyday practice because some of them were at low–
intermediate risk and others were at high–intermediate risk.
Consequently, CHA2DS2-VASc score was introduced to
improve predictive value for thromboembolic events in
patients at low and intermediate risk [11]. The utility of the
score goes beyond the benefits of risk stratification for
thromboembolic events. Apiyasawat et al. [19] reported it
to be an independent prognostic marker of mortality fol-
lowing hospitalization for AF. All elements of the CHA2-
DS2-VASc score are essential risk factors in cardiovascular
disease. Hypertension, diabetes mellitus, and congestive
heart failure were all found to be predictors of poor out-
comes following acute MI [20].
As pointed out in the introduction to this paper, there is
little published reports on the utility of CHA2DS2-VASc
score in risk stratification following acute MI. Poci et al.
[21] analyzed 2335 patients with acute coronary syn-
dromes and reported that CHADS2 score was associated
with long-term mortality (HR 1.38 95 % CI 1.28–1.48
P\ 0.0001) and stroke (HR 1.46 95 % CI 1.27–1.68
P\ 0.0001). Kim et al. [15] performed a retrospective
analysis of 15,681 patients with acute MI who were
enrolled in the Korean Working Group in Acute
Myocardial Infarction (KORMI) registry. They reported
that CHA2DS2-VASc score was associated with long-term
cardiac events (MI, all-cause death) (HR 1.384
P\ 0.0001). Interestingly, they found that CHA2DS2-
VASc score was a more important predictor in STEMI
patients (HR 1.455 P\ 0.0001) than in NSTEMI patients
(HR 1.298 P = 0.048). Piccini et al. [22] proposed a
modified R-CHA2DS2-VASc score by adding renal
function parameters (glomerular filtration rate and urea),
performance of a revascularization procedure, and history
of atrial fibrillation. Based on that modified R-CHA2DS2-
VASc score, a study showed a good calibration and high
discriminative performance of that score in the prediction
of post-discharge ischemic stroke and all-cause mortality
[23]. Recently, Podolecki et al. [16] studied 2980 patients
with acute coronary syndromes and no AF and reported
that an increment of one point in the CHA2DS2-VASc
score was independently associated with a 41 % increase
in stroke risk and a 23 % increase in mortality rate
(P\ 0.001 for both). Our results agree with the afore-
mentioned studies. We found that one-point increment in
CHA2DS2-VASc score was associated with an increase in
the risk of 12-month death by 24 % and for 12-month
stroke by 101 %. The present study validates prior find-
ings and refines their estimates among patients with dia-
betes mellitus. In addition, we demonstrated that the score
Fig. 2 a Kaplan–Meier in-hospital survival curves. b Kaplan–Meier 12-month survival curves. Group 1 versus 2 P = 0.06; group 1 versus 3
P = 0.001; group 2 versus 3 P = 0.04
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was negatively correlated with the time to stroke and the
time to death during follow-up. Furthermore, we demon-
strated that CHA2DS2-VASc score yielded a moderately
high negative predictive value (NPV) of 88 % for iden-
tifying patients at low risk of 12-month death and a high
NPV of 99 % for identifying patients at low risk for
12-month stroke. Similar observations were made by
Melgaard et al. [24] in a population of patients with heart
failure and no AF.
CHA2DS2-VASc score comprises a cluster of common
cardiovascular risk factors associated with thromboem-
bolism. It is possible it may identify underlying conditions
that may lead to AF, stroke, or death during follow-up. It is
reported to predict incident AF in patients without preex-
isting AF [25–27]. More importantly, CHA2DS2-VASc
score is recognized to be related to mortality and ischemic
stroke in patients without AF and stroke [28, 29], heart
failure [24], acute coronary syndromes [25], undergoing
CABG [30]. Interestingly, Podolecki et al. analyzing
patients with acute coronary syndromes failed to show any
discrimination performance of CHA2DS2-VASc score in
predicting incident MI during follow-up [16]. This finding
is in agreement with our observations. Moreover, cerebral
atherosclerosis is reported to be more common in patients
with higher CHADS2 score. Kim et al. [31] demonstrated
that patients with higher CHADS2 score had more carotid
Table 3 Predictors of in-hospital and 12-month mortality
In-hospital mortality
Unadjusted Adjusted
HR 95 % CI P HR 95 % CI P
CHA2DS2-VASc score (per one-point increment) 0.99 0.81–1.21 0.9 – – –
Twelve-month mortality
Unadjusted Adjusted*
HR 95 % CI P HR 95 % CI P
CHA2DS2-VASc score (per one-point increment) 1.31 1.11–1.54 0.001 1.24 1.06–1.45 0.008
Twelve-month myocardial infarction
Unadjusted Adjusted
HR 95 % CI P HR 95 % CI P
CHA2DS2-VASc score (per one-point increment) 0.78 0.52–1.16 0.22 – – –
Twelve-month stroke
Unadjusted Adjusted**
HR 95 % CI P HR 95 % CI P
CHA2DS2-VASc score (per one-point increment) 1.81 1.18–2.79 0.006 2.01 1.25–3.23 0.004
HR hazard ratio, CI confidence interval
* Adjusted for: history of myocardial infarction, left ventricular ejection fraction (per 1 % increment), successful percutaneous coronary
intervention (final TIMI 3 flow) in the culprit vessel, cardiogenic shock, time form symptom onset (per 1-h increment), platelet distribution width
(per 1fL increment), and platelet count (per 104/mm3 increment)
** Adjusted for: history of myocardial infarction, left ventricular ejection fraction (per 1 % increment), anterior myocardial infarction during
index hospitalization
Table 4 12-month follow-up
Group 1 N = 111 Group 2 N = 257 Group 3 N = 104 P
All-cause mortality, N (%) 10 (9.0 %) 43 (16.7 %) 27 (16.2 %) 0.003
Non-fatal myocardial infarction, N (%) 5 (4.5 %) 9 (3.5 %) 3 (2.9 %) 0.7
Stroke, N (%) 0 (0 %) 3 (1.1 %) 7 (6.7 %) 0.004
812 Acta Diabetol (2016) 53:807–815
123
(both extra- and intracranial) stenosis. This finding may, in
turn, result in an elevated risk of atherothrombotic stroke
even in the absence of AF.
Overall, CHA2DS2-VASc score seems to be a well-
known, simple tool that (1) comprises clusters of condi-
tions that are associated with poor outcomes, (2) may
increase the risk of incident AF in patients without pre-
existing AF leading to thromboembolic stroke, and (3)
may be associated with a more extensive atherosclerosis
leading to atherothrombotic stroke. All of the aforemen-
tioned mechanisms indicate the role of CHA2DS2-VASc
score in predicting an increased morbidity and mortality.
Taken together, these findings further support the poten-
tial role of CHA2DS2-VASc score in identifying high-risk
patients that may require more aggressive management
strategies.
Fig. 3 a Kaplan–Meier 12-month myocardial infarction-free survival curves. b Kaplan–Meier 12-month stroke-free survival curves. Group 1
versus 2 P = 0.8; group 1 versus 3 P = 0.02; group 2 versus 3 P = 0.03
Table 5 Receiver-operating characteristics curves identifying the discrimination thresholds of CHA2DS2-VASc score for predicting 12-month
mortality, non-fatal myocardial infarction, and stroke
Cut off AUC 95 % CI Sensitivity (%) Specificity (%) PPV (%) NPV (%) P
All-cause mortality [4 0.62 0.57–0.66 62 56 23 88 0.0003
Myocardial infarction 0.58 0.45–0.62 0.3
Stroke [4 0.75 0.71–0.79 91 54 5 99 0.0003





score and TIMI risk score for
long-term hospital mortality and
stroke
Cut off AUC 95 % CI
Twelve-month mortality
CHA2DS2-VASc score [4 0.67 0.63–0.71
TIMI risk score [4 0.60 0.56–0.65
Difference between areas CHA2DS2-VASc score and TIMI risk score 0.06
95 % CI -0.03–0.15
P 0.18
Twelve-month stroke
CHA2DS2-VASc score [4 0.75 0.71–0.79
TIMI risk score [4 0.52 0.48–0.57
Difference between areas CHA2DS2-VASc score and TIMI risk score 0.22
95 % CI 0.06–0.38
P 0.006
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Strengths and limitations
We investigated a real-life population of diabetic patients
with STEMI in which we did not exclude patients with
severe comorbidities, including cardiogenic shock. These
comorbidities may have predisposed some of the patients
to a greater risk of stroke. Single-center design has also its
shortcomings. We cannot exclude that some of the patients
have had undiagnosed AF, as vascular disease (acute MI in
this instance) is associated with a higher AF prevalence.
Moreover, we lack data on the development of AF during
follow-up, which may have resulted in the increased risk of
stroke. In any way, we were able to demonstrate the role of
CHA2DS2-VASc score in identifying patients at risk of
increased 12-month mortality and stroke regardless the
underlying mechanisms. Given the relatively low study
size, however, these promising results should be verified on
much larger cohorts.
Conclusions
In diabetic patients with STEMI and no previous AF,
median CHA2DS2-VASc score was high (4 points) and
predicted 12-month death and stroke. However, it failed to
predict in-hospital death and 12-month MI. CHA2DS2-
VASc score had a similar discrimination performance in
predicting 12-month mortality as TIMI risk score and a
better discrimination performance in predicting 12-month
stroke than TIMI risk score. Thus, it can serve as an
additive tool in identifying high-risk patients that require
aggressive management.
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